Advertisement

Safety and effectiveness of transdermal nicotine patch in smokers admitted with acute coronary syndromes

      An analysis of smokers admitted with acute coronary syndrome who received transdermal nicotine therapy and those who did not was performed. Propensity analysis was used to match patients. Transdermal nicotine therapy appears safe and does not have an effect on the mortality of patients with acute coronary syndromes.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Ryan T.J.
        • Antman E.M.
        • Brooks N.H.
        • Califf R.M.
        • Hillis L.D.
        • Hiratzka L.F.
        • Rapaport E.
        • Riegel B.
        • Russell R.O.
        • Smith III, E.E.
        • et al.
        1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction).
        Circulation. 1999; 100: 1016-1030
        • Gourlay S.G.
        • McNeil J.J.
        Antismoking products.
        Med J Aust. 1990; 153: 699-707
        • Hlatky M.A.
        • Califf R.M.
        • Harrell Jr, F.E.
        • Lee K.L.
        • Mark D.B.
        • Pryor D.B.
        Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery bypass surgery.
        J Am Coll Cardiol. 1988; 11: 237-245
        • Mark D.B.
        • Nelson C.L.
        • Califf R.M.
        • Harrell Jr, F.E.
        • Lee K.L.
        • Jones R.H.
        • Fortin D.F.
        • Stack R.S.
        • Glower D.D.
        • Smith L.R.
        • et al.
        Continuing evolution of therapy for coronary artery disease.
        Circulation. 1994; 89: 2015-2025
      1. Parsons LS. Reducing bias in a propensity score matched-pair sample using greedy matching techniques (paper 214-26). Available at: http://www2.sas.com/proceedings/sugi26/p214-26.pdf. Accessed on May 1, 2004.

        • Barry J.
        • Mead K.
        • Nabel E.G.
        • Rocco M.B.
        • Campbell S.
        • Fenton T.
        • Mudge Jr, G.H.
        • Selwyn A.P.
        Effect of smoking on the activity of ischemic heart disease.
        JAMA. 1989; 261: 398-402
        • Deanfield J.
        • Wright C.
        • Krikler S.
        • Ribeiro P.
        • Fox K.
        Cigarette smoking and the treatment of angina with propranolol, atenolol, and nifedipine.
        N Engl J Med. 1984; 310: 951-954
        • Dobson A.J.
        • Alexander H.M.
        • Heller R.F.
        • Lloyd D.M.
        How soon after quitting smoking does risk of heart attack decline?.
        J Clin Epidemiol. 1991; 44: 1247-1253
        • Cavender J.B.
        • Rogers W.J.
        • Fisher L.D.
        • Gersh B.J.
        • Coggin C.J.
        • Myers W.O.
        Effects of smoking on survival and morbidity in patients randomized to medical or surgical therapy in the Coronary Artery Surgery Study (CASS): 10-year follow-up.
        J Am Coll Cardiol. 1992; 20: 287-294
      2. Joint Commission on Accreditation of Healthcare Organizations. Specifications Manual for National Implementation of Hospital Core Measures. Oakbrook Terrace, Illinois: Joint Commission on Accreditation of Healthcare Organizations, 2003.

        • Greenland S.
        • Satterfield M.H.
        • Lanes S.F.
        A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch.
        Drug Safety. 1998; 18: 297-308
        • Lancaster T.
        • Stead L.
        • Silagy C.
        • Sowden A.
        Effectiveness of interventions to help people stop smoking: findings from the Cochrane Library.
        BMJ. 2000; 321: 355-358
        • Kimmel S.E.
        • Berlin J.A.
        • Miles C.
        • Jaskowiak J.
        • Carson J.L.
        • Strom B.L.
        Risk of acute first myocardial infarction and use of nicotine patches in a general population.
        J Am Coll Cardiol. 2001; 37: 1297-1302
        • Ottervanger J.P.
        • Festen J.M.
        • de Vries A.G.
        • Stricker B.H.
        Acute myocardial infarction while using the nicotine patch.
        Chest. 1995; 107: 1765-1766
        • Working Group for the Study of Transdermal Nicotine in Patients with Coronary Artery Disease
        Nicotine replacement therapy for patients with coronary artery disease.
        Arch Int Med. 1994; 154: 989-995
        • Joseph A.M.
        • Norman S.M.
        • Ferry L.H.
        • Prochazka A.V.
        • Westman E.C.
        • Steele B.G.
        • Sherman S.E.
        • Cleveland M.
        • Antonnucio D.O.
        • Hartman N.
        • et al.
        The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease.
        N Engl J Med. 1996; 335: 1792-1798
        • Tzivoni D.
        • Keren A.
        • Meyler S.
        • Khoury Z.
        • Lerer T.
        • Brunel P.
        Cardiovascular safety of transdermal nicotine patches in patients with coronary artery disease who try to quit smoking.
        Cardiovasc Drug Ther. 1998; 12: 239-244